Current status of proximal gastric vagotomy.
Proximal gastric vagotomy is nearing its twentieth year in clinical use as an operation for peptic ulcer disease. No other acid-reducing operation has undergone as much scrutiny or study. At this time, the evidence of such studies and long-term follow-up strongly supports the use of proximal gastric vagotomy as the treatment of choice for chronic duodenal ulcer in patients who have failed medical therapy. Its application in treating the complications of peptic ulcer disease, which recently have come to represent an increasingly greater percentage of all operations done for peptic ulcer disease, is well-tested. However, initial series suggest that it should probably occupy a prominent role in treating some of these complications, particularly in selected patients, in the future. The operation has the well-documented ability to reduce gastric acid production, not inhibit gastric bicarbonate production, and also minimally inhibit gastric motility. The combination of these physiologic results after proximal gastric vagotomy, along with preservation of the normal antropyloroduodenal mechanism of gastrointestinal control, serve to allow patients with proximal gastric vagotomy the improved benefits of significantly fewer severe gastrointestinal side effects than are seen after other operations for peptic ulcer disease.
Schirmer
B D
BD
Department of Surgery, University of Virginia Health Sciences Center, Charlottesville 22908.
D002927:Cimetidine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004381:Duodenal Ulcer / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D004630:Emergencies; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D011708:Pylorus; D012008:Recurrence; D013276:Stomach Ulcer / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D014629:Vagotomy, Proximal Gastric / Q000009:adverse effects / Q000379:methods
D002927:Cimetidine